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 A simple signal processing based on frequency-domain analysis is introduced. 
 Identification and removal of the undesired noise contributions from the analytical 
signal. 
 Approach developed to enhance the sensitivity of optical biosensors. 




An approach to enhance the sensitivity of optical biosensors is developed. It is based 
on patterning strips of biochemical probes and signal processing (frequency-domain 
analysis, FDA) to the resulting analytical data after a biorecognition assay. This paper 
introduces FDA, demonstrates for the first time its potential in real bioanalytical 
systems, describes its critical parameters, and discusses how to optimize them to 
efficiently exploit this approach for optical biosensing. The results show that FDA 













from the analytical signal arising from a biorecognition event of interest, thus increasing 
signal-to-noise ratios and, therefore, enhancing the sensitivity of the analysis. In this 
study, we proof the concept with a model immunassay system for IgGs detection 
(BSA/anti-BSA) that achieves a sensitivity enhancement of up to 3 orders of 
magnitude, and then FDA is also demonstrated in a sandwich immunoassay to quantify 
casein that reaches a limit of detection of 4 ng/mL (174 pM). Beyond these particular 
assays, this work also addres to stablish the basis of this approach and to provide keys 
to stimulate future developments that expand the potential of FDA to other 
biorecognition assays, transduction systems, and applications. 
 
KEYWORDS 




Biosensors are booming due to their advantages and performances [1–3], as well as 
their capability to comply the ASSURED (affordable, sensitive, specific, user-friendly, 
rapid and robust, equipment free, and deliverable to end users) criteria outlined by the 
World Health Organization [4]. As in any measurement science, analyzing 
biorecognition events is also susceptible to signal contributions from external 
physicochemical sources (noise) which dramatically decreases the sensitivity and 
reliability of the analysis [5]. Therefore, in addition to optimize the biochemical 
parameters of the assay [6,7], effective approaches to identify and discriminate the 
analytical signals of interest are crucial to reach maximal performances in biosensing 
[8].  
Digital filtering (DF) is a widely employed strategy to address this issue in bioanalytical 
systems [8,9], especially its implementation based on the Fourier transform [10–12]. As 
schematized in Figure 1a, Fourier transform filters convert the image scanned after the 
biointeraction into its corresponding frequency counterpart. Then, frequency signals 
within a selected spectral range (ideally containing the major noise contributions) are 
attenuated, and the filtered data is finally transformed back to an image. Thought 
offering good solutions for many analytical applications, these DF strategies keep 
considerable undesired noise contributions in the resulting data. Moreover, the proper 













threshold filtering conditions above which desired physicochemical information is not 
removed together with the noise [9].  
Herein, we present frequency-domain analysis (FDA) as a tool to enhance sensitivity in 
biorecognition assays by effectively identifying the analytical signals coming from the 
biointeractions of interest and discriminating them from every noise contribution. As 
schematized in Figure 1b, FDA relies on patterning (on solid substrates) biorecognition 
assays as straight and equidistant strips, which generate periodic signals when they 
are scanned. These periodic signals become unified in a single frequency peak when 
they are converted into their frequency counterpart using the Fourier transform, 
whereas undesired contributions are spread along the spectrum. Therefore, by using 
the intensity of the resulting peak as analytical magnitude, noise can be efficiently 
discriminated in order to analyze biointeractions in a more sensitive fashion. Schaefer 
and Chau explored this strategy to discriminate voltage fluctuations in an ink-based 
optical system [13]. Hereinafter, we introduce for the first time FDA for biochemical 
analysis, describe and discus the key parameters for its implementation, and 
experimentally demonstrate the performance improvement provided by this 
methodology. 
Although not directly addressed in this study, it is worth mentioning that the capability 
of FDA to selectively discriminate the signals coming from the biointeraction of interest, 
could also be useful to minimize artifacts coming from nonspecific binding in 
prospective developments [14]. Since the adsorption of nonspecific binding agents 
tends to present a random (not periodic) distribution along the assay surface, it should 
display a negligible contribution in the resulting frequency spectrum. Therefore, 
similarly to the concept behind focal molography and diffraction-based sensing [15–18], 
this phenomenon could also be potentially exploited by FDA to solve nonspecific 
binding problems typically observed in the analysis of complex biological matrixes. 
On the other hand, FDA is also potentially compatible with any bioanalytical approach 
based on imaging or scanning biorecognition assays on solid substrates. As a proof of 
concept, in this paper we implement it in colorimetric biorecognition assays patterned 
on standard compact disks (as analytical platforms) analyzed by a disk drive tailored to 
scan the assay response. This is an inexpensive and high-throughput sensing strategy 
[19,20], herein selected to provide insights into the point-of-care potential of FDA.  
As biorecognition assays, in this paper we first address a model immunoassay based 
on bovine serum albumin to quantify specific IgGs, a well-known system typically used 













Then, FDA is also applied to a sandwich immunoassay to determine casein. Casein is 
a family of related phosphoproteins that represents about 80% of the protein content in 
milk, whose predominant proteins have a molecular weight of approximately 23 KDa. It 
is estimated that 0.6-2.5% of children and 1% of adults have some form of allergy 
towards dairy products [22], which supports the importance of the quantification and 
standardization of this target protein. Moreover, both non-processed and digitally 
filtered (Fourier filter) microarrays are used along the study as reference approaches 
typically used in the field, in order to compare performances and demonstrate the 
potential of the new approach herein presented. 
 
2. MATERIALS AND METHODS 
2.1. Materials 
Carbonate buffer (50 mM sodium carbonate, pH 9.6), PBS-T (8 mM Na2HPO4, 2 mM 
KH2PO4, 137 mM NaCl, 2.7 mM KCl, 0.05 % (v/v) Tween-20, pH 7.4), and washing 
solutions were filtered through a 0.22 µm pore size membranes before use. Bovine 
serum albumin (BSA), anti-BSA polyclonal antibodies produced in rabbit, gold labeled 
anti-rabbit polyclonal antibodies produced in goat (GAR-Au), casein, and silver 
enhancer solutions were supplied by Sigma-Aldrich (Madrid, Spain). Anti-casein and 
HRP-conjugated anti-casein monoclonal mouse antibodies were kindly provided by 
Ingenasa S.A. (Madrid, Spain). Tetramethylbenzidine (TMB) substrate was from SDT 
GmbH (Baesweiler, Germany). Bulk DVD-R disks were purchased from MPO Ibérica 
(Madrid, Spain). DVD drive (LG HL-DT-ST DVD-RAM GSA-H42N) was from LG 
Electronics Inc. (Englewood Cliffs, NJ, USA). Silicone-Free adhesive plastic film was 
purchased from Ultron Systems, Inc (Moorpark, CA, USA). Matt black PVC adhesive 
sheets were supplied by Aironfix – Eon Paper S.L (Manresa, Spain). Bungard CCD 
drilling machine was from Bungard (Karo, Germany). 
2.2. Incubation Masks 
To perform the striped patterning of biorecognition assays required for FDA, we 
developed custom adhesive incubation masks containing striped chambers, to be 
attached on the assay substrate (Figure 2a and Figure S1). For that, PVC adhesive 
sheets and silicone-free adhesive plastic films were cut into 12 x 12 cm squares, and 
they were attached to the non-adhesive part of silicone-free film. The PVC part of this 
two-layer structure was used to confer firmness to the mask, whereas the silicone-free 
adhesive plastic was selected since it does not leave residues on the substrate 













have same pattern as the striped assay, thus altering the result of the analysis. The 
masks were patterned with 10 sets of 15 strips each using the drilling machine with a 
500 µm diameter tungsten carbide drill (feed speed of 800 mm·min−1 and rotational rate 
of 30000 rpm). The configuration of the masks was designed to generate a set of 
parallel strips in the resulting scanned image, considering that the employed disk drive 
scans the platform by following a spiral track at constant linear velocity.  
2.3. BSA Immunoassay 
First, a model immunoassay based on BSA as probes and IgGs as targets was used in 
this study. For the microarray approach, BSA solutions (50 µg/mL in carbonate buffer) 
were arrayed (40 nL/spot) on the polycarbonate surface of DVDs using a noncontact 
printer (AD 1500 Bio-Dot, Inc, Irvine, CA, USA) under controlled temperature and 
relative humidity (25 °C and 95%, respectively). On the other hand, to pattern the 
assays as strips, 1 mL of BSA (50 µg/mL in carbonate buffer) was dispensed onto the 
disk and distributed using a dummy polycarbonate plate (12 cm diameter, 0.6 mm 
thick). To attach the proteins on the polycarbonate surface by physical immobilization 
(passive adsorption) [23], in both cases BSA solutions were incubated for 3 h at room 
temperature, and then the disk was washed with PBS-T, rinsed with deionized water, 
and dried by centrifugation. Afterwards, in the strips patterning protocol, incubation 
masks were placed onto the disk and a slight pressure was applied in order to attach 
them. 
To perform the selective IgG biorecognition, anti-BSA solutions in PBS-T (40 µL/array 
in microarrays and 300 µL/strip set in FDA) were incubated (20 min, room temperature) 
in concentrations ranging from 10 µg/mL to 31.6 pg/mL by serial dilutions of 1/100.5, 
including 0 ng/mL. After this incubation, the assay platforms were rinsed with PBS-T, 
deionized water, and dried by centrifugation. Then, 1 mL of GAR-Au (1/200 dilution in 
PBS-T) was dispensed onto the disk, distributed using a dummy polycarbonate plate, 
incubated for 20 min at room temperature, and washed and dried again. Finally, 1 mL 
of silver enhancer solution was dispensed onto the disk and distributed as before. After 
5 min at room temperature, the disk was washed with deionized water and dried by 
centrifugation. As a result, insoluble silver precipitates whose surface concentration 
depends on the magnitude of the biointeraction, are obtained on the assay surface. 
Real images of exemplary platforms after both microarray and striped assays are 
shown in Figure S2. 













An immunoassay based on antibodies as probes and casein as target was also studied 
in this work. To pattern microarrays for this immunoassay, monoclonal anti-casein 
antibody solutions (40 µg/mL in carbonate buffer) were arrayed (40 nL/spot) on the 
polycarbonate surface of DVDs using the noncontact printer under controlled 
temperature and relative humidity (25 °C and 95%, respectively). To pattern as strips, 1 
mL of monoclonal anti-casein antibody solution (40 µg/mL in carbonate buffer) was 
dispensed onto the disk and distributed using a dummy polycarbonate plate. In both 
cases, the disks were incubated overnight at 4 ºC, and then rinsed with PBS-T and 
deionized water, and dried by centrifugation. 
Afterwards, casein solutions (40 µL/array for microarrays and 300 µL/strip set for FDA) 
ranging from 100 µg/mL to 100 pg/mL in PBS-T and blanks, were incubated for 20 min 
at room temperature in both cases. Then, the disks were washed, rinsed, and dried as 
before. Next, 1 mL of HRP-conjugated anti-casein antibodies (1/20000 dilution in 
PBS-T) was dispensed onto the disk and distributed using a dummy polycarbonate 
plate, incubated for 20 min at room temperature, and washed and dried again. Finally, 
1 mL of TMB substrate solution was dispensed onto the disk and distributed as before. 
After 8 min at room temperature, the disk was washed with deionized water and dried 
by centrifugation. In this case, insoluble dark blue immunoreaction products are 
generated on the assay surface, whose magnitude is proportional to the concentration 
of casein. 
2.5. Disk Drive Imaging 
The DVD drive used in this study as analytical scanner was controlled by custom 
software (BioDisk) running on a personal computer. As described elsewhere [19], the 
reading process relies on a focused laser beam that scans the disk following an spiral 
trajectory at linear velocity, which adsorbs and scatters light when it hits the 
immunoreaction products. This interaction causes variations in the intensity of the 
reflected laser beam, and these light attenuations correlate with the analyte 
concentration. Finally, the drive converts these analog signals into binary, and they are 
sent to the computer and arranged as images. 
2.6. Microarray Data Processing 
As commented before, in this study we assessed FDA by comparing its performance 
with both raw and digitally filtered (DF) microarrays as reference methods. Raw 
microarray images were directly generated by the disk drive imaging system, as 
described above. On the other hand, to obtain the DF microarrays, raw images were 













the Fast Fourier transform and process their frequency spectra, as schematized in 
Figure 1a. Different threshold filtering values were assessed, which removed nearly 
half of the noise and kept close to constant assay signals (Table S1), thus improving 
the sensitivity of the system. From these results, 100 KHz was selected as a threshold 
filtering value to attenuate the high-frequency noise in DF microarrays. 
GenePix software (Axon Inst, Union City, CA, USA) was used to quantify signals of 
both raw and DF microarrays. Analytical signals of each array were calculated by 
averaging the intensity of all the replicated microarray spots and subtracting their 
background. Noise values were experimentally obtained as the standard deviation of 
10 blank replicates (0 ng/mL of target), and signal-to-noise ratios (SNR) were 
calculated by dividing the signal of each assay between its noise. 
2.7. FDA Data Processing 
Scanning the biorecognition assays patterned as strips on the assay surface leads to 
images constituted by sets of parallel lines, as observed in Figure 1b(i) and Figure 2. 
To process these images, they were first cropped into 15 mm width and 4 mm height 
rectangles with Photoshop CS4 (Adobe Systems Inc., San Jose, CA, USA). Next, a 
custom Matlab algorithm was used to apply the Fast Fourier transform to the scanned 
images, in order to obtain the frequency spectrum of every data row (Figure 1b(ii)) and 
to average all of them in a single one, from which using the height of the resulting peak 
as analytical signal (Figure 1b(iii)). In the FDA approach, experimental noise values 
were calculated as the standard deviation of the peak intensity of ten blank replicates. 
The employed Matlab algorithm also transforms the magnitude in the horizontal axis of 
the resulting frequency spectra, from frequency to period (distance). This 
transformation enables to visualize the resulting FDA peak centered in the period value 
in which the striped biorecognition assays are patterned. In this system, the correlation 
of frequency and period is described by the equation below:  
𝑃𝑒𝑟𝑖𝑜𝑑 =  
𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔 𝑟𝑎𝑡𝑒 · 𝑟𝑒𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦
     (1) 
where sampling rate is the number of measurements per time unit took by the scanning 
system, and resolution is the length of the assay substrate scanned by each one of 
these measurements. The sampling rate and the resolution of the disk drive scanner 
employed in this study are 2000 KHz and 6.98 µm/pixel, respectively. As a result, with 
the incubation mask herein developed, FDA signals were mainly concentrated at 13918 














3. RESULTS AND DISCUSSION 
3.1. FDA Parameters 
In this section we describe the main parameters that affect FDA and discuss how to 
deal with them in order to fully exploit the analytical performance of this approach. First, 
the width of the assay strips and the separation between them were investigated. 
These two parameters (together with the features of the analytical scanner) determine 
the resulting profile of the patterned assays in the scanned image, which strongly 
affects the FDA response. As shown Figure S3, sinusoid profiles concentrate the signal 
in a single (fundamental) peak, whereas other profiles (such as squared and triangular) 
distribute the signal also in additional harmonic peaks.  
To achieve a sinusoid profile, the width of the strips and the separation between them 
have to be the same, namely, the duty cycle must be 50%. On the other hand, as 
inferred from simulations considering the optical resolution of the scanning system 
employed in this study (Figure S4 and Eq. S1), the desired sinusoid profile can be 
obtained by patterning 500 µm width assays strips within 1 mm periods. 
Different methods were investigated to experimentally create these striped patterns of 
proteins on the polycarbonate surface of the assay substrates, such as non-contact 
printing and soft lithography [24,25]. Among them, the best results were obtained by 
creating masks with striped holes, and then attaching them on the assay surface in 
order to incubate biochemicals in a patterned fashion (Figure 2a). These masks were 
initially made of PDMS and PVC adhesive sheet, but they left residues on the assay 
surface after their removal, and these residues became patterned in the gaps between 
the assay strips. Since gaps and strips have the same period, the signal contributions 
coming from both parts were unified in the frequency peak, which increases the 
resulting noise and reduces the performance of FDA. To avoid this handicap, silicone-
free adhesive plastic film was selected to create the incubation masks (Figure S1). This 
material does not leave residues on the assay substrate after its removal, and it 
enables a clean patterning process that results in well-defined assay strips with the 
desired sinusoid profile in the scanned image (Figure 2b-c). 
The number of strips is another important parameter in the FDA response. As 
theoretically (Figure S5) and experimentally (Figure 3a) observed, frequency peaks 
become narrower when the number of strips increase. Moreover, the resolution of the 
frequency spectrum improves together with this number (Figure 3a). The stepwise 
shape of this curve is due to the Fast Fourier transform used to obtain the frequency 













minimal computational requirements. This method rounds up the number of processed 
data to the next power of 2, and each step in Figure 3a corresponds to one of those 
values in the number of pixels in each row of the scanned image. The number of strips 
becomes especially important in the design of prospective multiplexed FDA systems 
based on assay strips patterned according to different periods (to sense different 
targets), thus generating distinct frequency peaks for each analyte in a single FDA 
assay. 
Therefore, since higher spectral resolutions and narrower peaks favor FDA analysis 
(especially for multiplexed FDA), the potential sensitivity to be achieved scales up 
together with the number of strips, and consequently with the area employed by the 
assay. On the other hand, a greater number of strips require higher volumes of 
bioreagents and samples. In high-resolution bioanalytical scanning systems, this issue 
can be easily addressed by decreasing the size of the strips. A set of 15 strips was 
chosen in this study, since it is a smaller number that involves great resolution and 
narrow peaks. 
The length of the strips was also investigated. The importance of this parameter lies in 
the fact that the frequency peaks also comprise small contributions of random noise. 
Since FDA averages frequency spectra from every raw of data (Figure 1b), the longer 
the strips are the larger number of scanned rows, and consequently, the noise (the 
standard deviation) decreases with the square root of the length, according to the 
Bienaymé formula [26]. The results in Figure 3b show that the noise remains rather 
constant after 4 mm of strip length, so this value was selected for the subsequent 
experiments. 
As presented in Figure 4, the expected FDA result was successfully obtained with the 
optimized assay patterning conditions. Despite the sinusoidal shape of the scanned 
assay strips, very weak harmonic peaks are also observed in the spectra, which may 
be generated by minor profile irregularities in the resulting experimental strips. 
However, the intensity of these harmonics is negligible compared to the one of the 
fundamental peak. It must be noted that we used distance magnitudes instead of 
frequencies for the horizontal axis of the resulting FDA spectra. For optical setups that 
scan the assay substrate at constant velocity, both variables have an inverse and linear 
correlation (Eq. 1). However, using distances provides intuitive and practical FDA 
readouts, in which the fundamental peak appears centered in the distance value that 














We also investigated the effect, on the FDA performance, of random and systematic 
errors in the assays patterning. For that, we modelled different modifications of the 
strips and assessed their repercussion in the resulting frequency peak. As an example 
of a random error, we considered the absence of strips randomly distributed along the 
strips set. It represents an extreme case for a random patterning error that diminish the 
averaged intensity of particular strips within a set. For instance, in the present work, 
this error could come from imperfections when filling the chambers with the probe 
solution. As shown Figure S6, these random errors affect the resulting FDA response, 
and the intensity of the resulting frequency peak decreases linearly with the number of 
missing strips. Also, it is worth to note that the position of the removed strips presents a 
negligible repercussion in the resulting peak intensity (RSD < 0.1 % in all cases). 
On the other hand, as a systematic patterning error, we considered a systematic 
deviation of the strip widths along the whole set of strips. For example, this error could 
come from experimental deviations in the method employed to create the striped 
pattern. In this particular development, it could be generated by inaccuracies in the 
diameter of the drill used to pierce the incubation masks. As shown in Figure S7, this 
systematic modification of the strips width modifies the intensity of the frequency peak 
according to a Gaussian trend. Although this intensity becomes suppressed in both 
extremes of the curve, it is worth to highlight that it only decreases less than 2 % when 
the width varies up to a 10 % ( 50 µm in this work) around the central width value 
selected to obtain the desired sinusoid profile. 
3.2. Model Immunoassay System 
In order to experimentally assess the performance of FDA in real assays, this strategy 
was compared with raw (non-filtered) and digitally filtered (DF) microarrays. Raw 
microarrays were obtained directly from the imaging system, their DF counterparts 
were processed with a low pass Fourier filter using optimized cut-off values to remove 
high-frequency noise (Table S1), and FDA was performed as described in the previous 
section.  
For this comparison, we used a model immunoassay system based on immobilizing 
BSA on the assay surface and quantifying selective IgGs in solution. A wide range of 
IgG concentrations were analyzed by all the approaches in the same conditions. 
Sensitivity was evaluated by means of SNRs, and limits of detection (LOD) and 
quantification (LOQ) were considered as the experimental IgG concentration 













As observed in Figure 5, well-correlated dose-response curves were obtained in all the 
cases. More interestingly, raw microarrays display the lowest SNR values, DF 
microarrays slightly increase SNRs, and FDA approach exhibits a dramatic 
improvement that has an impact on the LOD and LOQ. Table 1 summarizes the 
analytical parameters obtained from these experimental dose-response curves. It can 
be observed that DF leads only to a two-fold noise reduction compared to raw 
microarray. However, FDA achieves a close-to-zero noise and reaches a sensitivity 
enhancement of about 2-3 orders of magnitude for this model immunoassay system, 
which enables the detection of 30 pg/mL (200 fM) of IgG. 
3.3. Casein Immunoassay 
After proving the concept of FDA with a model system, this section aims to 
demonstrate the potential of this strategy in other immunoassays, and to provide 
insights into real applications to analyze food allergens. For that, we applied FDA to a 
sandwich immunoassay to quantify casein. Instead of using gold-labelled secondary 
antibodies together with silver signal enhancement as in the previous section, the 
signal development was here based on HRP-labelled primary antibodies followed by 
TMB precipitation. 
In this study, the performance of FDA for this casein immunoassay was assessed and 
compared to raw microarrays. DF microarrays were omitted in this assessment, since 
this strategy displayed a poor improvement in the previous section. As before, 
sensitivity was evaluated by means of SNRs, and LOD and LOQ were considered as 
the target concentration corresponding to SNR = 3 and SNR = 10, respectively. 
As observed in Figure 6, both dose-response curves display the expected sigmoidal 
response, and the characteristics (binding affinities and signal developing strategy) of 
this casein immunoassay lead to lower signals than the previous BSA immunoassay. 
The graph shows that, also in lower signal conditions, FDA generates significant SNR 
enhancements in the dose-response curve. As summarized in Table 2, FDA reduces 
the noise and improves LOD about two orders of magnitude compared to the raw 
microarray assay format, reaching a sensitivity of 4 ng/mL (174 pM) of casein.  
 
4. CONCLUSION 
FDA is a practical approach to reduce noise and improve sensitivity in optical 
biosensing. As experimentally demonstrated in this study in two different systems, the 













2-3 orders of magnitude by just applying a simple signal processing algorithm, 
compared to reference microarray systems. FDA must potentially provide higher 
sensitivity enhancements in bioanalytical systems comprising greater contributions of 
unwanted signals, such as in simple and low-cost biosensing setups. Therefore, this 
approach entails important strengths to reduce the resources required to develop 
biosensors without sacrificing their analytical performance, which suggests simpler and 
cheaper systems for point-of-care analysis. Besides, the capability of FDA to reject 
unwanted signals introduces appealing perspectives to develop new bioanalytical 
systems that provide solutions to the problems associated with nonspecific binding in 
the analysis of complex matrixes. Also, the multiplexing potential of FDA could be 
enhanced by patterning (in different periods) multiple biorecognition assays on the 
same substrate area, and then discriminating their FDA peaks in the frequency 
spectrum. Moreover, our results point towards prospective FDA advances to develop 
highly sensitive assays exploiting different optical events (fluorescence, light 
interference, SPR, etc.) applied to determine a wide range of targets (proteins, DNA, 
cells, small molecules, etc.).  
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Figure 1. Scheme of the signal processing approaches studied in this work. (a) Fourier digital 
filtering: (i) scanned raw microarray image and its cross section, (ii) the corresponding 
frequency spectrum obtained by Fourier transform, which is filtered to attenuate high-frequency 
contributions, and (iii) the resulting filtered microarray image and its cross section. (b) FDA 
approach: (i) scanned image of the patterned assay strips, (ii) two exemplary frequency spectra 
of single data rows, and (iii) the resulting frequency spectrum generated by averaging the one of 














Figure 2. Striped patterning of biorecognition assays. (a) Schematic representation of the 
patterning of biological probes using the adhesive incubation mask with striped chambers 
herein developed. (b) Scanned image experimentally obtained from a patterned BSA 
immunoassay and (c) its corresponding sinusoidal-shaped averaged profile. 
 
Figure 3. Number of strips and their length. (a) Experimental curve of number of strips versus 
both peak width and resolution in the frequency spectrum. Data fitted to Equation S2 













Experimental results of the effect of the strips length on the resulting noise in the FDA analysis. 
Data fitted to Bienaymé formula (R2 = 0.872). 
 
Figure 4. Exemplary experimental frequency spectrum for a patterned BSA immunoassay, 
representing period values in the horizontal axis. See Figure 2b and 2c for the scanned image 
counterpart of this spectrum. Inset graph zooms in in the short period range, to show the 
harmonic peaks. 
 
Figure 5. Dose-response curves for the FDA assessment with a model immunoassay system. 
Note the two different SNR scales in this graph. Experimental data fitted to four-parameter 
logistic equation (R2raw = 0.998, R2DF = 0.995, and R2FDA = 0.997) [27]. The two points within the 
hook effect area observed at high IgG concentrations in the striped dose-response curve were 
omitted in the fitting process [28]. Inset plot focuses on the LOD and LOQ zones. In this 
experiment, 15 replicated spots were analyzed for raw and DF microarray, and sets of 15 strips 













Figure 6. Dose-response curves for the FDA assessment with a sandwich immunoassay for 
casein analysis. Experimental data fitted to four-parameter logistic equation (R2 = 0.999 in both 
fits). Inset plot zooms in in the LOD and LOQ concentration ranges, where the green and red 
dashed lines mark the SNR thresholds for LOQ and LOD, respectively. In this experiment, 
averaged values and standard deviations were calculated from 3 replicated microarray dots and 

















Table 1. Analytical parameters for the FDA assessment with the model immunoassay system. 
 noise (a.u.) max. SNRa LOQ (ng/mL) LOD (ng/mL) 
Raw microarray 218 30 95 6 
DF microarray 114 49 42 4 
FDA 4 1840 0.08 0.03 
aSNR value at the steady state of the logistic fitting. 
 
 
Table 2. Analytical parameters for the FDA assessment with the sandwich immunoassay for 
casein analysis. 
 noise (a.u.) max. SNRa LOQ (ng/mL) LOD (ng/mL) 
Raw microarray 177 47 462 129 
FDA 6 303 27 4 
aSNR value at the steady state of the logistic fitting.     
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